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ABSTRACT
We seek to discover new drug candidates for the excitatory amino acid transporter 3
(EAAT3) for the treatment of Obsessive Compulsive Disorder (OCD). We hypothesize that
decreasing the glutamatergic transmission via EAAT3 intervention will create an amelioration of
the symptoms of OCD. For this we have prepared in-silico binding calculations to identify a better
compound that can stimulate EAAT3 and decrease glutamatergic transmission. This research will
help us further understand and elucidate the role of glutamate in the neural mechanisms of this
illness, which to date remain inconclusive. Those areas of study are significant because, until now,
there is no effective medication for patients with OCD. Currently, the first line of medication is
the use of serotonin reuptake inhibitors (SRI); however, most of the patients undergoing
treatment still experience some of the symptoms.
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CHAPTER 1: INTRODUCTION
1.1. Introduction to Obsessive Compulsive Disorder
Obsessive Compulsive Disorder (OCD) is a neurological disease that is characterized by
persistent,

unwanted

thoughts

(obsessions)

and

routines

or

ritualistic

behaviors

(compulsions).[1,2] Generally this disease does not originate from a traumatic experience, but
rather the onset of the disorder seems to be pervasive and gradual. The symptoms often change
over time, but there is no direct link between an initial traumatic event and a symptom.[2,3]
Individuals affected by OCD suffer from intrusive thoughts that lead to an increase in anxiety,
from which they find it very difficult to avoid adopting certain behaviors. Even though the
affected individuals might find the behavior inappropriate and stressful, they cannot control
it.[4,3] Symptoms of OCD may be motivated by factors other than fear, such as feelings of
incompleteness or “not just right” experiences.[5] If left untreated, OCD can become a disabling
and chronic illness.[3,6] Through empirical research,[5] this illness can be divided into four different
subtypes as shown in table 1. One example of OCD of the contamination subtype is the case of
a man with OCD that was washing and polishing his neighbors’ automobiles without permission.
He was arrested but was later released when he explained to the officers that he had OCD. On
his way out of the station, he began cleaning the police cars.[4]
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Table 1. Summary of the different types of behaviors shown in OCD.

* Until recently, The American Psychiatric Association Diagnostic and Statistical Manual for Mental
Disorders fifth edition (DMS-5), has categorized Hoarding as a distinct anxiety disorder under the
category of OCD-related.

It is known that OCD is comorbid with various mental illnesses; amongst them, the
disorder with the highest comorbidity with OCD is Tourette’s Syndrome (TS). Individuals with TS
have a 50% chance of developing OCD.[7,2,5] Other disorders that are also comorbid with OCD
include: Autism Spectrum Disorders (ASDs), Unipolar Mood Disorder, Schizophrenia,
Huntington's Disease, Sydenham's Chorea, Attention-Deficit/Hyperactivity Disorder (ADHD),
Depression, Addiction, Post-Traumatic Stress Disorder (PTSD), Generalized Anxiety Disorder,
Panic Disorder, and Social Phobia.[4,2,8,9,10,11] The direct correlation between OCD and other
mental illnesses is not well understood; however, these previously mentioned disorders might
share a common dysfunction in similar areas of the brain.
In OCD, compulsions may serve to prevent increasing anxiety levels after encountering a
trigger; paradoxically, the compulsions can make the individual uncomfortable and, as a result,
elevate anxiety. Figure 1 gives an illustration of the OCD process. Even though OCD is classified
2

as an anxiety disorder, the fifth edition of the Diagnostic and Statistical Manual (DSM-V) has
separated OCD from other anxiety disorders, and it appears as one of several disorders which
prominent features are obsessive preoccupation and repetitive behaviors.[12] Studies correlating
anxiety disorders and OCD found that even though OCD and some anxiety disorders (Alexithymia
and Anxiety Sensitivity) share some symptoms, OCD does not follow the classical model
(traumatic event leads to conditioned anxiety or behavior) and additionally, anxiety seems to be
controlled by a stronger correlation of emotion-aversion and symptom manifestation.[13,14] The
diagnosis of OCD is given by the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), a
questionnaire that assesses the symptoms associated with OCD and gives a score, which is
indicative of the severity of the condition.[4]

Figure 1. Schematic of steps involved in OCD.
Performing the compulsion can decrease
anxiety, but this results in reinforcing the
obsession-compulsion loop through classical
conditioning. Paradoxically, performing the
ritual can cause anxiety to the individual.

1.2. Pathophysiology of OCD
Statistics reveal that, in the United States, approximately 5 million Americans
(approximately 2.3% of the total population) are affected by OCD at one point in their lives,[4] and
the World Health Organization (WHO) has classified OCD as the fourth major mental illness with
significant morbidity.[6] As previously mentioned, OCD is a detrimental disease that significantly
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decreases the quality of life of the individual. In a recent study, people with OCD reported having
a lower quality of life than individuals with schizophrenia.[5] The current obstacle in the treatment
of OCD is that there is no effective medication yet and the underlying neurological mechanism is
not well understood.
1.2.1. Neuroimaging Studies (Brain Regions Affected by OCD)
Neuroimaging studies reveal the areas of the brain and the circuitry that is affected in
OCD. Overall, these studies show a comparison between a healthy individual and an individual
with the disorder. Additionally, it is possible to observe improvements in the brain under a
specific treatment or medication. Through nuclear magnetic resonance imaging (MRI) studies,
OCD patients have consistently indicated an anomaly in the orbitofrontal cortex (OFC), anterior
cingulate cortex (AAC), basal ganglia, and thalamus.[4,6] From the previously mentioned areas, the
most important region is considered to be the basal ganglia, due to its close relation with the
glutamatergic transmission and its direct feedback (communication) with the thalamus and
cerebral cortex; lesions to the basal ganglia have been reported to produce OCD.[4] In conjunction
with the basal ganglia, MRI studies have also reported hyperactivity in the anterior circulate
cortex (ACC), striatum, and orbitofrontal cortex (OFC).[56,62,97] Positron emission tomography
(PET) and other neuroimaging studies (Such as: H1MRI) reveal a relationship between levels of
the neurochemical metabolites and dysregulation of the aforementioned regions; studies have
consistently shown a dysregulation in glutamate/glutamine concentration in the OFC (higher),
striatum (higher), ACC (lower), and left caudate cortex (lower).[30,56,63] Another study that
corroborates the importance of glutamate/glutamine in OCD is the quantification of
neurotransmitters in the cerebrospinal fluid, a study that reveals a correlation between symptom
4

severity and an elevated level of glutamate and glycine in the cerebrospinal fluid of OCD
patients.[3,56] Other incidents that provide further evidence of the areas of the brain affected by
OCD are focal brain injuries: people who had strokes affecting the inferior parietal, basal ganglia,
caudate, and/or posterior frontal lobe have acutely shown OCD symptoms.[7,4,15] The relationship
between the areas of the brain being overstimulated and the dysregulation of neurotransmitters
led to the current model of OCD, which emphasizes the aberrant cortico - striato - thalamo cortical (CSTC) modulation,[16,5,6,17] from which glutamate is the major excitatory
neurotransmitter,[14,18] and which is also known to interact extensively with serotonin, gamaaminobutyric acid (GABA), and dopamine.[6]
1.2.2. Genetic Studies of OCD
Although the neurobiology and etiology of OCD is not fully understood, there are studies
that suggest that this disease has a genetic basis, which predisposes certain individuals to develop
OCD. Hereditary studies do not provide a concise genetic anomaly that can be correlated to the
disease, but rather give an indication of a mutated gene that can be passed on to generations. In
addition, it also proves that the disease is not exclusively a result of environmental factors:
hereditary studies reveal that monozygotic twins have a higher probability (80–87%) for both to
develop to OCD, in comparison to that of dizygotic twins (47–50%).[5,17] Development of this
disease could also be explained through epigenetics, in which it is believed that through DNA
methylation or other DNA modification mechanisms that can be influenced by environmental
stimuli, some changes can occur, which can influence gene expression.
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There have been several genome association studies, most of which are able to locate
some relevant genes, but they are not able to consolidate their data with other results, or the
data does not reach a very significant trend to be a concise association. We are only going to
focus on the most relevant genes for the case study. Some of the genes associated with the
glutamate neurotransmission system include the SLC1A1,[19,4,6,20,21,17] which is a gene that encodes
the Excitatory Amino Acid Transporter (EAAT)1/3, and is located on the post-synaptic and perisynaptic membrane. This transporter is highly expressed in the cerebral cortex, striatum, and
thalamus.[17] Another glutamate transporter gene associated with OCD is the SLC1A2 gene, which
encodes the EAAT2 glutamate transporter.[19,22,17] Both of these glutamate transporters maintain
the glutamate concentration within normal range. The final glutamate-related genes are the
GRIK2 (which codes for a kainate receptor subunit) and GRIN2B (which codes for the NR2B
subunit of N-methyl-D-aspartate (NMDA) receptors).[23,22,17] Some genes associated with
dopaminergic transmission include SLC6A3, which codes for a dopamine active transporter
protein (DAT1) and its function is to provide dopamine clearance from the pre-synaptic cleft;
DRD3, which codes for the dopamine receptor D3, which has been associated with schizophrenia
and Parkinson’s disease;[22,17] and two serotonin-related genes: 5-HTTLPR (also known as
SLC6A4), which codes for a serotonin transporter that helps in the serotonin clearance, and 5HTR2A, which codes for a serotonin receptor that is associated with excitation, behavioral effects,
learning, and anxiety.[4,6,22,24]
1.2.3. Genetic Animal Models in OCD
Animal models provide an insight to the probable molecular and genetic mechanism of
the disease; additionally, they can help us test and tailor new drugs for the disease being
6

analyzed. The D1CT-7 (Ticci mouse) was among the first animal models of OCD: a model that
correlates to the dopamine genetic abnormalities found in humans. This mouse expresses an
intracellular form of cholera toxin that leads to a chronic potentiation of the D1+ neurons, which
in turn produces an over-activation of glutamatergic output in the striatum.[25] The brain regions
in which the cholera toxin transgene is expressed in DICT-7 mutant mice overlap with the neural
circuitry implicated in OCD.[25] These mice, in addition to exhibiting OCD (compulsive grooming),
also exhibit Tourette Syndrome (TS)-like behaviors (tics). Treatment with clonidine is shown to
decrease tics, but not OCD symptoms. This mouse model would be most appropriate for the
comorbid condition of OCD –TS, rather than just OCD.
The animal model that correlates to the glutamate system in OCD is the DLGAP3 (SAPAP3)
Knockout mice. This model exhibits excessive grooming, and has defects in glutamatergic
transmission at cortico-striatal synapses, which could be related to an abnormal NMDA receptor
subunit NR1 (GRIN1), NR2B (GRIN2B) and NR2A (GRIN2A) composition, found in the postsynaptic density of striatal neurons. The use of a lentiviral vector reduced OCD-like
behaviors.[22,25,17] The treatment with fluoxetine, a selective serotonin reuptake inhibitor (SSRI)
reduces the grooming behavior in mice.[4,5,25] The problem with this model is that there is no
consistent association across SNP studies in humans.[17]
The final animal model presented here is the SLITRK5 Knockout. This model also exhibits
excessive grooming and anxiety behaviors; additionally, this mouse model has impaired corticostriatial circuitry and abnormal glutamate activity. The SLITRK5 Knockout mice share some
similarities with DLGAP3 (SAPAP3) Knockout mice, in which both exhibit an increase in
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orbitofrontal cortex activity, and report changes in NMDA subunit composition, as well as
glutamate receptor composition.[22,17] Treatment with fluoxetine reduces the OCD behaviors in
this mouse model, just like in the previous model.[22]
There are other animal models; however, they were excluded due to the lack of evidence
in correlation to OCD. Although they might have displayed OCD-like symptoms, they might have
exhibited other comorbid conditions, or more work is required to establish predictive validity.
Examples of these models include dopamine transporter knockdown (DAT KD) mice, which might
be more suitable to study in TS with comorbidity with OCD due to the syntactic grooming they
displayed.[25] Another example is the 5-HT2C Knockout mice, which might be more suitable for
anxiety models due to the inconsistent anxiety behaviors displayed.[25]
1.2.4. Other Correlations with OCD Development
In addition to genetic and environmental factors (epigenetics), there are other factors
that can be associated with the onset of OCD. One theory associates the pathogenesis of OCD to
an autoimmune response triggered by a streptococcal infection. This condition is known as
Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections
(PANDAS), and the population that is at risk of this phenomenon is between the ages of 3 to 14.
PANDAS is thought to originate through Group A beta-hemolytic streptococcal infections; via a
phenomenon known as molecular mimicry, the antibodies mistakenly recognize and "attack" the
basal ganglia, a mechanism similar to the cardiac effects produced from rheumatic fever. The
antibodies have not been definitely identified yet.[4,26,27,17] Children with OCD derived from
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PANDAS might have additional symptoms such as anxiety, urinary urgency, oppositional defiant
disorder, and mood swings, in comparison with a patient with OCD only.[4]
There is also some evidence suggesting that nitric oxide (NO) might be an important
element in OCD, since some studies found that OCD patients have higher NO levels than healthy
individuals, and that these levels are positively correlated with the severity of OCD symptoms. [7]
The evidence is supported by a decrease in NO levels as the OCD patients receive SSRI, antidopaminergic drugs, and the NMDA antagonist memantine.[7] However, this correlation could be
consequence of the

glutamate–nitric oxide–cGMP pathway, where the activation of an

ionotropic glutamate receptor such as kainate, AMPA, or the NMDA receptor (previously proven
to have SNP in humans), leads to increased calcium in the post-synaptic neuron, which in turn
binds to calmodulin and activates neuronal nitric oxide synthase (nNOS). [28] In this case, NOS
might be a side effect of the glutamate dysregulation in OCD.
Another phenomenon that can be related to OCD consists of reports that the female
hormonal cycle might trigger or exacerbate OCD symptoms, as gonadotropine-releasing
hormone (GnRH) agonists were reported to ameliorate OCD symptoms.[7] Other hormones that
are correlated to the severity of the symptoms of OCD include vasopressin, oxytocin, and
adrenocorticotropin; however, their influence on the severity of the symptoms is not fully
understood.[7]
1.2.5. Pharmacological Drugs that can cause OCD-like symptoms
The molecular mechanism of the drugs that can cause or exacerbate OCD may provide a
deeper insight of the neural pathways by which this disease functions. Recreational drugs that
9

produce

OCD-like

symptoms

are:

amphetamines,

methylphenidate,

meta-

chlorophenylpiperazine (ecstasy), and cocaine.[4] Methylphenidate and cocaine act as dopaminenorepinephrine reuptake inhibitors; by binding to these transporters, they increase the
dopamine and norepinephrine levels in the synaptic space. Amphetamines also increase the
levels of dopamine and norepinephrine in the brain, although its mechanism of action is through
their effects on monoamine transporters. Additionally, amphetamines also inhibit SLC1A1
genetic activity. In regard to ecstasy, its mechanism of action is as an agonist of serotonin
receptors; the strongest binding happens at the 5-HT2B and 5-HT2C transporters, and it has been
reported to exacerbate OCD in patients who have consumed.[4]
Prescription medications that produce OCD-like symptoms include ropinirole,
pramipexole, and pergolide, which are dopamine agonists, especially of the D3 receptor.[4]
Topiramate has also been reported to induce obsessive–compulsive symptoms;[17] however, the
mechanism is not fully understood. Although not a prescription drug, arginine, which can be
obtained as a supplement, has been linked to exacerbation of OCD; this may be related to the
fact that arginine is a NO agonist and precursor that elevates the level of nitrides, and increases
marble-burying behavior in mice.[7]
Some drugs that have induced OCD in mice include 8-hydroxy-2-di-n-propylamino-tetralin
hydrobromide (8-OHDPAT) and quinpirole.[7] The case of 8-OHDPAT has become an animal model
for OCD; upon administration of 8-OHDPAT (5-HT1A agonist), mice decrease spontaneous
alternation (natural tendency of rats to explore novel places). The disadvantage of this model is
that an acute administration of the drug is required for the model to have face validity; however,
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it does seem to decrease OCD symptoms when supported by the administration of a serotonin
reuptake inhibitor, as will be discussed later. Chronic administration of quinprinole (D2/D3
agonist)[27] can induce compulsive checking and ritual-like motor acts in rats. This OCD-like
behavior is decreased by the administration of serotonin reuptake inhibitors, giving this model
face validity.[19]
1.3. Treatment Options
As with most neurological disorders, there is a wide range of treatment options for
patients with OCD. The first line of treatment approved by the FDA is the use of selective
serotonin reuptake inhibitors (SSRI).[7,27] Additionally, the American Psychiatric Association
recommends that individuals engage in cognitive behavioral therapy (CBT) focusing on exposure
and response prevention therapy. The problem with OCD is that due to the complexity of this
disorder, about 50% of the patients do not respond to current pharmacological medications,[29,30]
and patients who do respond to the pharmacological interventions might not feel a complete
relief of the symptoms.[18,5,15] The treatment paradigm for most OCD medications is to begin with
a low dose and increase gradually. The disadvantage of this is the myriad of side effects a patient
can experience. It is also recommended, once the individual starts with a treatment, to follow up
for at least three months, since most of the medications do not provide immediate symptom
relief.[31] It is also important to mention that, even though anxiety is a big component of the
disease, anxiolytic drugs are not effective in alleviating obsessions and compulsions.[7]
The most accepted method to measure OCD in humans is the Yale-Brown Obsessive
Compulsive Scale (Y-BOCS),[32,27] a rating scale intended to be used as a semi-structure interview.
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The interview assesses and rates the severity and type of symptoms with respect to time spent,
interference, distress, resistance, and control in patients with Obsessive Compulsive Disorder
(OCD).[32] The obsessions and compulsions are rated in a scale from 0 to 4, where zero is classified
as none and four is classified as extreme or incapacitating. The array of questions in this rating
system has shown internal consistency and validity for patients with OCD. The Y-BOCS test can
be viewed at the appendix section of this proposal. Most of the studies presented in this proposal
measure symptom reduction by Y-BOCS, with the exception of animal models, for they have a
different paradigm to measure OCD symptoms. To better understand the treatment options used
in OCD patients, the treatments are going to be divided in pharmacological treatment, alternative
medicine, psychological treatments, and surgical interventions.
1.3.1. Pharmacological Treatments
Pharmacological treatments refer to the drugs that have a synthetic origin. The most
popular medications for OCD are the SRI; however, there are other medications that target
ionotropic, glutamatergic, and norepinephrine receptors. Experimental treatments for OCD are
based on the neural circuitry being affected by OCD.

1.3.1.1. Serotonin Reuptake Inhibitors
Selective serotonin reuptake inhibitors (SSRI) and serotonin reuptake inhibitors (SRI) are
drugs that block the reuptake of serotonin (by binding to a transporter protein); as a result, there
is an increase in the serotonin levels in the pre-synaptic cleft. SSRIs are designed with a specific
biological target, compared to SRI, which do not really have a specific biological target, and thus
can bind to other transporters. SSRI are the first line of treatment for OCD. These medications
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are usually prescribed as antidepressants; however, they seem to alleviate the symptoms of OCD.
The most probable mechanism of action of SRI drugs might be through inhibition of glutamatergic
transmission in the orbitofrontal cortex.[5,15] As previously stated, individuals with OCD display
excessive baseline activity of excitatory glutamatergic neurons; therefore it is hypothesized that
the increase in serotonin levels will ameliorate glutamatergic transmission, resulting in symptom
reduction, although there is no definitive mechanism as to how this occurs.
Most commonly, a patient with OCD will try two to three drugs before finding the one
that works best for them.[1] The most common side effects associated with SSRI and SRI are dry
mouth, sweating, constipation, drowsiness, tremor, sexual side-effects, weight gain, nausea,
sleeplessness, and headaches; rare cases include manic episodes and seizures.[1] As previously
stated, not all OCD patients respond well to SRI or SSRI; however, for patients who are resistant
to SRI treatment, another drug is added in an attempt to increase effectiveness. This is known as
“augmentation therapy,” which consists on the addition of serotonin reuptake inhibitors, typical
and atypical antipsychotic drugs, glutamatergic agents, or natural remedies.[1] Safe and approved
methods of augmentation therapy include psychological treatments like CBT. Table 2 illustrates
and describes the SSRI and SRI that have been used in the treatment of OCD.
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Table 2. Brief description of the SRI and SSRI medications used for the treatment of OCD. The commercial
name of the compounds is given in parenthesis.

Serotonin Reuptake Inhibitors
Drug Name

Data
Clomipramine is the oldest and best studied of the SRI
medications. It is a highly selective inhibitor of serotonin
reuptake (5-HTT). Usually prescribed when other SSRI

Clomipramine*
treatments are not effective. Although clomipramine
(Anafranil)
may be slightly more effective than other SSRI, it is
usually not prescribed because there are more adverse
side effects, among which is the potential for cardiac
toxicity, including QTc prolongation.[1,4,33]
Fluvoxamine demonstrated similar efficacy but superior
tolerability over clomipramine. Fluvoxamine, in addition
Fluvoxamine*
to functioning as an SSRI, also works as a σ1 receptor
(Luvox)
agonist (trans-membrane ER chaperon protein that is
linked to depression).[4,1]
Fluoxetine interacts with cytochrome P-450 (CYP) 2D6
Fluoxetine*
to produce its active metabolite norfluoxetine. This drug
(Prozac)
has a weaker binding that fluvoxamine.[4]
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Structure

Paroxetine is one of the most potent and selective SSRI;
Paroxetine*

additionally, it inhibits the reuptake of norepinephrine

(Paxil)

more than other SSRI. Paroxetine is more likely to cause
birth defects and has category D rating from the FDA.[4,6]
In addition to being an SSRI, sertraline inhibits the

Sertraline*

reuptake of dopamine more than the other SSRI.

(Zoloft)

Sertraline tends to be associated with a higher rate of
psychiatric side effects.[4]
Escitalopram is the S-enantiomer of citalopram. There
have been studies that demonstrate the efficacy in the

Escitalopram
treatment of OCD; however, this SSRI does not have FDA
(Lexapro)
approval for treating OCD.[4] The main use of this drug is
to treat major depression disorders.
Citalopram is an SSRI that, like escitalopram, can
Citalopram

function for the treatment of OCD, but is not approved

(Celexa)

by the FDA for that purpose.[4] One of the most
important side effects of citalopram and escitalopram is
a QTc prolongation, especially in overdose.

*FDA approved to treat OCD. Additionally, have received highest category of evidence to treat OCD,
according to the Guidelines of the World Federation of Societies of Biological Psychiatry (WFSBP). [4,1,3]

1.3.1.2. Ionotropic Glutamate Receptors
These medications are not approved by the FDA for the treatment of OCD; however, due
to genetic evidence in single nucleotide polymorphism (Grin2B, [codes for NMDA subunit] and
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GRIK2/GRIK3 [codes for a kainate subunit]) and key neuro-metabolites (glutamate)), it appears
that there might be a connection between the ionotropic receptors and OCD. Studies have
favored the NMDA receptors because they have the highest affinity for glutamate (EC50 1 μM);[20]
additionally, they have been linked to anti-compulsive effects in animal models of OCD.[34] The
other ionotropic glutamate receptors which also have potential for OCD target medication are
the kainate (KA) receptor and α-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA)
receptor. These three ionotropic receptors are activated by glutamate and mediate most of the
rapid synaptic excitation throughout most of the vertebrate central nervous system. [35]
Furthermore, some of these medications can be used as augmentation therapy to enhance the
effects of the SSRI.[4] Table 3 provides more information about the medicine targeted at
ionotropic receptors for the treatment of OCD.
Table 3. Brief description of the medications used in OCD that target ionotropic receptors. The
commercial name of the compounds is given in parenthesis.

Pharmacological Treatments Involving Ionotropic Glutamate Receptors
Drug Name

Data
D-cycloserine is a partial NMDA agonist that has had mixed
results in OCD patients. While some patients report an

D-

improvement in conjunction with cognitive behavioral

cycloserine

treatment (taken one hour before session),[17] other studies

(Seromycin)

report that the data is not significantly different.[6] It has
also been reported that D-cycloserine-treated rats display
decreased compulsive lever pressing.[17]
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Structure

Dizocilpine is a potent NMDA receptor antagonist (channel
blocker).[36] In mice, Dizocilpine showed no effect on lever
pressing experiments, but mice from another study
Dizocilpine
decreased marble-burying behavior; however, these mice
(MK-801)
displayed an increased locomotion in comparison to the
control.[4] Additionally, it has been shown that this drug has
antidepressant-like effects.[37]
Memantine

is

a

non-competitive

NMDA

receptor

antagonist.[4] It has shown efficacy as an augmentation
Memantine

agent in refractory OCD in several case reports.[17]
Memantine has also received FDA approval for the
treatment of Alzheimer's disease.
Amantadine is an NMDA receptor antagonist. It has

Amantadine

reduced marble-burying behavior in mice, with greater
effectiveness compared to memantine and riluzole.[6,17]
Ketamine is an NMDA receptor antagonist. Studies have
revealed that it has anti-OCD properties.[37] It has also

Ketamine
shown antidepressant effects in OCD patients with
comorbid depression.[37]
NBQX is an AMPA receptor antagonist. Administration of
NBQX
this drug showed no effect on marble-burying behavior in
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mice,[7] demonstrating the importance on NMDA receptor
activity in OCD.
Riluzole has been reported to inhibit the kainate and NMDA
receptors. It is also a glutamate antagonist (release
inhibitor) and stimulates glutamate uptake by astrocytes.
Its mechanism of action has not been fully elucidated.
Riluzole

Riluzole was found to be effective for children with OCD,

(Rilutek)

and as an augmentation agent for patients who are SRIresistant. However, riluzole showed no effect on marbleburying behavior in mice, which could have been because
the model lacked face validity on inducing the OCD
symptoms.[7,6,17]

1.3.1.3. Antipsychotics
Antipsychotics can be divided in two categories: typical (refers to the first-generation
antipsychotics) and atypical (second-generation antipsychotics, which also act on serotonin
receptors). Most of these drugs are for patients who suffer from schizophrenia or bipolar
disorder. Antipsychotic treatment is only given to patients whose OCD is SRI-resistant. This
treatment targets dopaminergic and serotonergic loops as receptor agonists.[17] The use of
antipsychotics for the treatment of OCD began as one study reported an improvement of OCD
symptoms with the use of haloperidol as augmentation therapy with fluvoxamine; it is
hypothesized that the dopamine (D2) receptors might play a role in the attenuation of the OCD
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symptoms.[5] The main problem with this medication is the adverse side effects. Most
antipsychotics are used as augmentation therapy, and in some instances they may exacerbate
OCD symptoms.[4] It is difficult to assess which antipsychotic is effective as augmentation therapy,
as some studies may show opposite results; such is the case of clozapine, which is reported to
induce, aggravate, and alleviate OCD symptoms.[33] Table 4 gives a brief overview of the
antipsychotic medications used in the treatment of OCD. Perhaps the limited efficacy of these
drugs is due to their ability to act on certain serotonin receptors as agonists; however, a
complication arises when the drugs act on dopaminergic receptors as well.
Table 4. Brief description of the antipsychotic medications used to treat OCD. The commercial name of
the compounds is given in parenthesis.

Pharmacological Treatments Involving Antipsychotics
Drug

Data

Structure

a) Clozapine

These six drugs are atypical antipsychotics. The

(Clozaril1)

majority of the studies, except for a few with small

b) Quetiapine

sample sizes[38] (shown below), reveal that none of

a)

c)
(Seroquel1)
c) Olanzapine

these drugs are effective in treating

OCD.[4,17]

Olanzapine augmentation with SSRI has been reported
d)

(Zyprexa)

to be as successful as

risperidone.[6]

In a 12-week, open label trial of aripiprazole,
d) Ziprasidone
(Geodon1)

significant improvement of OCD symptoms was e)
demonstrated[6]
f)

19

b)

e) Paliperidone

A study found that clozapine down-regulates the

(Invega)

protein produced by SLC1A1 (EAAC1/3) in the

f) Aripiprazole

cingulate cortex of the rat,[17] supporting the existence

(Abilify1)

of a relationship between glutamate in the synaptic
cleft and OCD.
There are also reports that these drugs, except for
ziprasidone, can cause OCD in other patients who do
not have it.[4,39]
Risperidone is a more potent serotonin antagonist

Risperidone

compared to dopamine antgonist. This atypical

(Risperdal)

antipsychotic has been tested in OCD with limited
benefit.[4,1,6]
Haloperidol is an antipsychotic medication that is a D2
(dopamine) receptor agonist, as well as a serotonin

Haloperidol

agonist at a higher dose. When used as an

(Haldol)

augmentation treatment with SSRI, haloperidol
reduces symptoms of OCD, particularly in patients
with comorbid tics.[1,5]
Has a higher binding affinity than haloperidol, acting

Pimozide

as a D2 receptor agonist. It has been reported to

(Orap)

modestly reduce symptoms of OCD, when used in
augmentation treatment with SSRI.[1]
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1.3.1.4. Other Pharmacological Interventions
This section refers to other drugs that have been tested as potential treatments for OCD.
Most of them are used as augmentation therapy, and are not approved by the FDA to treat OCD;
however, some seem to be effective for some patients. Table 5 provides data for these other
pharmacological interventions that have been tested for the treatment of OCD.
Table 5. Brief description of the alternative pharmacological interventions that have been used to treat
OCD. The commercial name of the compounds or abbreviation is given in parenthesis.

Alternatives to OCD Medications
Drug

Data
L-tryptophan is essential for the body to produce
serotonin. Based on the evidence that serotonin levels
affect OCD, L-tryptophan seems like a good candidate for

L-tryptophan
enhancing serotonergic transmission in the CNS. People
who have tried L-tryptophan in combination with an SRI
have had very limited benefit.[34,1]
Inositol is an isomer of glucose, and it was once considered
to be part of the B vitamin complex.[34] Inositol has had
mixed results in OCD treatment. Overall, studies suggest
Inositol
that for inositol to be effective, a high concentration[1,34]
(more than 1,000 mg) must be prescribed, since a lower
concentration does not produce significant results.[2]
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Structure

Lithium is known for its use in bipolar disorder and
Lithium

depression. Augmentation therapy of lithium versus
-------------------placebo found no benefit in lithium

augmentation.[4,1]

N-acetylcysteine (NAC) is a cysteine derivative that is less
susceptible to oxidation, and more soluble in water than
cysteine. NAC has been proposed as a treatment for OCD
because it can inhibit synaptic glutamate release through
the cysteine-glutamate exchange. When cysteine levels
Nare increased, so is the extracellular glutamate in the extraacetylcysteine
synaptic space, which in turn leads to stimulation of
mGluR2/3 receptors and, as a consequence, inhibition of
synaptic glutamate release.[38,6,67] NAC augmentation with
fluvoxamine results in a significant improvement in OCD
symptoms.[34,17]
Serotonin –

Although they inhibit serotonin in conjunction with

norepinephrine norepinephrine, so far they have not yielded significant
reuptake

symptom improvement. Among the tested drugs are

inhibitors

venlafaxine,

(SNRI)

levomilnacipran.[4,39]

Ondansetron

Ondansetron is a 5-HT3 (serotonin) receptor antagonist.

(Zofran)

When used as monotherapy in SRI-resistant OCD patients,

------------duloxetine,
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milnacipran,

and

it was reported that half of the patients in a small trial
group presented symptom reduction.[4]
Pregabalin inhibits glutamate release via blockade of
Pregabalin

calcium channels. Beneficial effects on OCD symptoms in
combination with SSRI have been reported.[6]

Dronabinol

Two case reports showed Improvement in refractory OCD

(THC)

with the cannabinoid Dronabinol.[6]
The MAOI have a history of being used for depression. The
disadvantage is that they inhibit the oxidation of

Monoamine

monoamines, which can bring upon a myriad of side

Oxidase

effects; in addition, they can also create some

Inhibitors

dependence. Phenelzine (Nardil) and tranylcipramine
------------------

(MAOI)

(Parnate) are MAOI that have been used to treat OCD, and
were reported to have limited benefits, being less effective
than SRI medications.[1]
Morphine has shown efficacy in treatment-resistant OCD.
The mechanism is not fully understood, but it is thought to

Morphine
act by inhibiting glutamate release through disinhibition of
serotonergic neurons.[6]
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1.3.2. Alternative Medicine Treatments
Alternative medicine can elicit fewer side effects than typical pharmacological
medication. Most of the time, alternative medicine is used as augmentation therapy or as a
supplement to ameliorate the severity of the symptoms. Most of the alternative medicines are
based on herbal medicine, and are taken as infusions or as food supplements. Approximately
44% of patients hospitalized for acute care of various psychiatric disorders have used herbal
medicine to ameliorate their illness.[32] The problem with some of these remedies is that some
phytochemicals may interact with prescription medicine in a negative way, which may reduce
the potency of the medication. One of the main obstacles of herbal medicine studies is that the
dosage of the phytochemicals cannot be accurately assessed.
Table 6. Brief description of the alternative natural medications used to treat OCD. The common name is
given in parenthesis.

Herbal Medicine

Data
A well-known plant used for the treatment of depression and anxiety. It is

Hypericum

believed to increase binding sensitivity to 5HT1A receptor and inhibit

perforatum

neuronal release of glutamate. The mayor constituents are hyperforin and

(St. Johns worth)

hypericin.

No

significant

results

have

occurred

against

OCD

symptoms.[40,41,42]
It is commonly used as a hepato-protective agent. In preclinical studies it
Silybum
has been found to increase serotonin levels in the cortex. It has been
marianum
shown to reduce symptoms of OCD.[34] The mayor phytochemical is the
(Milk thistle)
flavonoid complex known as silymarin.
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Methanolic
Traditionally used to increase appetite. It exhibits significant antiextract of
compulsive effects in marble-burying behavior tests in mice, and the
Benincasa hispida
effect may be attributed to an enhanced serotonergic function. Its effects
fruit (winter
are comparable to fluoxetine.[43]
watermelon)
Used in traditional Iranian medicine as an anxiolytic. A study shows that it
[23,44]

Echium amoenum

significantly reduces OCD and anxiety.

In addition, animal models

(Borage)

have revealed borage as having anxiolytic and sedative effects
comparable to diazepam.[21]

Lagenaria
This food item has shown to attenuate OCD in marble-burying
siceraria
behavior.[21]
(Calabash)

Doctors in the field of homeopathic medicine suggest to avoid chorine,
dimethylaminoethanol, copper, or folic acid supplements, because they often exacerbate OCD
symptoms,[22] but advise to take methionine, s-adenosyl methionine, calcium, magnesium, B-6,
inositol, betaine anhydrous, and zinc supplements, because they help in the treatment of OCD.[2]
Other alternative methods include acupuncture, mindfulness meditation, yoga breath work,
progressive muscle relaxation, and meridian tapping.[21]
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1.3.3. Psychological Treatments
The recommended psychological treatment for people with OCD is cognitive behavior
therapy (CBT) focused in exposure and response prevention therapy. In this approach, the
patients are exposed to the anxiety-provoking stimulus, and the therapist encourages the patient
to avoid the use of compulsions in order to foster habituation. The goal of this treatment is to
teach the patients with OCD to be less anxious around the stimulus, and avoid performing rituals.
For this treatment to be effective, 10 to 20 hours of therapy are necessary to achieve favorable
outcomes. This particular treatment has a success rate as high as 80 percent in the reduction of
the symptoms.[32,11,33] Due to the success of this therapy, it is considered the psychological
treatment of choice for OCD.[32] CBT can be performed as an individual therapy or as a group
therapy. Studies have found small difference between the individual versus the group therapy.
The downside of psychological treatments is that success of the therapy is dependent on the
experience of the therapist, and the commitment of the patient to the treatment. For patients
who are using this therapy as augmentation, it is recommended to avoid benzodiazepine drugs
(anxiolytic) because they affect short-term memory and learning.[1,33]
1.3.4. Surgical Interventions
These surgical interventions are uncommon, and are only performed where affected OCD
patients have exhausted conventional therapies. These operations target the cortico-striatothalamic-cortex (main brain circuitry in OCD).[54,6] One of the surgeries performed is the anterior
cingulotomy, which involves a lesion on the anterior cingulated cortex and cingulum. [6,15]
Another neurosurgical procedure is deep brain stimulation, which consists on implanting a
pacemaker to send electrical impulses, which stimulate a specific area of the brain; in the case of
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OCD, stimulation is given to the internal capsule and/or the adjacent ventral striatal region, which
may be effective for severely affected OCD patients.[6]
1.4. Summary of OCD
OCD is a complex mental disorder, and its pathology has not been fully elucidated. People
who suffer from this disorder experience an obsession and, to alleviate the stress associated,
they perform a compulsion, which can be characteristic to every individual. The current
treatment options are not effective for all patients, and most of the treatments carry unwanted
side effects. Through the neuroimaging studies, experts in the field have derived a model that
correlates important neurotransmitters with parts of the brain that are involved in the disorder.
Through genetic studies, we can correlate specific proteins and link them to the disorder protein,
such as NMDA receptor, kainate receptor, EAAT 1/3, as well as serotonin receptors, and
dopamine transporter D3. As for pharmacological interventions, we can deduce that blocking
dopamine receptor D1 can exacerbate the symptoms; however, for dopamine receptor D2, the
drugs had limited effect and the results are inconclusive. In regard to psychological treatment,
CBT yields good results and can be used as an augmentation therapy for the patients. The other
treatment options deal with traditional medicine and can yield good results; however, more
research is needed to better elucidate the bioactive components of these remedies.
Through the amount of evidence obtained from OCD in correlation to the areas of the
brain being affected, there is a proposed glutamate dysfunction model. This model makes use of
the CSTC circuitry and it is represented in figure 2. In short, there are two pathways by which
signal transduction occurs in the CSTC circuitry. The first pathway is called the direct pathway; in
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it, the striatum sends an inhibitory GABA signal to the globus pallidus interna, which in turn
decreases inhibitory action in the thalamus and, as a result, there is an excitatory glutamate signal
sent from the thalamus to the OFC and AAC. In the second pathway (indirect), the striatum sends
and inhibitory GABA signal to the globus pallidus externa, which decreases its inhibition to the
subthalamic nucleolus (STN) and, as a result, the STN sends an excitatory glutamate signal to the
GPi, which in turn inhibits the thalamus. According to the OCD dysfunction model, there is an
overstimulation of the direct pathway, which in turn leads to glutamatergic overstimulation in
the AAC and OFC.

A)

B)

Figure 2. Illustration of a simplified diagram of the Cortical Striatal Thalamic Cortical (CSTC) circuit. A)
Dashed lines represent GABA neurotransmission, and solid lines represent glutamate
neurotransmission. Red arrows represent the direct pathway and blue arrows represent the indirect
pathway. Orange arrows represent the dysfunction or areas being overstimulated by patients with OCD.
B) Brain areas of the CSTC circuit.

1.5. Excitatory Amino Acid Transporter (EAAT) and OCD
Understanding the neurochemistry of OCD is central for the advancement of more
effective medication, and as presented previously there seems to be a strong correlation
between OCD and glutamate. Experimental evidence indicates that, by blocking or decreasing
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NMDA receptor function, an improvement in OCD symptoms is observed. However, blocking
NMDA receptor activity can produce severe side effects. Decrease in NMDA receptor activity can
also be elicited by decreasing glutamate in the synaptic cleft via stimulating EAAT3.
The EAAT protein family belongs to the solute carrier 1 transporter family and it is
responsible for glutamate transport in different parts of the body, this family of transporters
exhibit up to 60% amino acid sequence identity with each other.[45,46] EAAT1 and EAAT2 are found
predominantly in glial cells on the brain. EAAT3 and EAAT4 are predominantly expressed in
neurons. Finally EAAT5 is mostly found in the retina. We will focus on the EAAT3 protein because
it is selectively enriched in the neurons of the hippocampus, basal ganglia, cerebellum, and
olfactory bulb,[47,48] which are some of the areas implicated in OCD; thus, stimulating EAAT3 can
lower extracellular glutamate concentrations in these areas and ameliorate the OCD symptoms.
From the previously presented evidence, targeting the EAAT3 protein for the treatment of OCD
seems to be a viable option. The mechanism of action of EAAT3 involves the initial binding of
three Na+ and one H+ ions with glutamate or aspartate across the membrane while the
transporter countertransports one K+ ion (Figure 3).[47,49] It is believed that the EAAT3 proteins
assemble in trimmers, with each unit functioning like a monomer.[49,50] This transporter is
localized in the post-synaptic cleft of neurons but it is also found in the kidney, where it functions
as glutamate/aspartate transporter. Loss of function of this transporter can result in dicarboxylic
aminoaciduria.[46,50]
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Figure 3. Blue arrow depicts the
transport of glutamate, and the red
arrow depicts the countertransport
of potassium ions across the
transporter.

To date, there is no crystal structure of the EAAT3 transporter; as a result, most
computational studies utilize the crystal structure of the glutamate transporter homologue
(GltPh), from Pyrococcus horikoshii, an archeal homolog that shares a 37% sequence identity with
the EAAT family. Initially this might appear as a poor model to follow; however, the homology is
much higher for residues near the binding pocket, reaching around 60% in this region.[11]
Furthermore, almost all of the residues shown to be involved in the binding of the ions and
glutamate in GltPh are conserved in the EAAT family. These computational calculations have
yielded important information in regard to inhibitors and allosteric regulators for EAAT
proteins.[8] Table 7 provides a list of the relevant molecules known to bind to the EAAT3 protein.
Table 7. Brief description of the EAAT3 substrates.

Substrate
a) L-Glutamate

Data

Structure

Gluatamate and aspartate are the

a)

b)

endogenous ligands of the EAAT3
b) L-Aspartate

protein; however, it is also known that
EAAT3 is able to transport the amino

c) L-Cysteine

acid cysteine.[51,52]
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c)

L-trans-Pyrrolidine-2,4-dicarboxylic
L-trans-2,4acid is a glutamate uptake blocker; it
pyrolidine
increases the extracellular glutamate
dicarboxylate
levels in the synaptic cleft.[53]
Clonidine reduces the response to LClonidine

glutamamte uptake in EAAT3
proteins.[47]
L-β-threo-benzyl-aspartate, NBI-59159

a)

and L-TBOA inhibit the neuronal
EAATs.[54] L-β-threo-benzyl-aspartate is
a) L-β-threomore specific for EAAT3 [54,55] DL-TBOA
benzyl-aspartate
has proven to be an effective inhibitor,
b) NBI-59159
specially toward EAATs 2 and 3. This
c) DL-TBOA
molecule has also been employed in
radiolabel studies to find the binding
affinity to the EAATs proteins.[56,57]
L-(-)-threo-b-hydroxyaspartate is a
L-(-)-threo-b-

substrate that resembles the

hydroxyaspartate endogenous activity of l-glutamate, in
EAATs 2 and 3.[50]
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b)

c
)

Threo-3-methylglutamate is an EAAT2
Threo-3inhibitor, but at higher doses it also
methylglutamate
inhibits EAATs 3 and 4.[50]
a) Lidocaine

a)

b) Isoflurane

All of these molecules have been

c) Propofol

reported to increase EAAT3

d) Benzodia-

activity.[27,58, 59]

zepine
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c)

b)

d)

CHAPTER 2: SIGNIFICANCE AND INNOVATION
Up to date, the first line of medication against OCD is the use of selective serotonin reuptake
inhibitors (SSRI); however, due to the limited success of SSRI, many patients remain significantly
impaired by their symptoms. Even though the pathophysiology of OCD is not fully elucidated,
there is a strong line of evidence correlating the excitatory neurotransmitter glutamate and the
symptom severity of OCD. This theory is supported by genetic studies, neuroimaging studies,
animal models, small clinical studies, and case reports presented in this proposal. As such, a novel
therapeutic intervention targeting the glutamatergic pathway is needed. This proposal will focus
on the dysregulation of the glutamatergic pathway in OCD via the EAAT3 protein.
The research strategy is to pharmacologically intervene EAAT3 by computational methods.
This research changes the vision of the field, being that it is the first study to target the EAAT3
activity in OCD patients. Although there has been development of drugs to target these
receptors, these drugs are used for anxiety disorders. This new approach aims to yield data that
will improve the understanding of glutamate regulation in OCD. The results of this study will yield
an improved understanding of the neurobiology and etiology of OCD.
2.1 Hypothesis
We hypothesize that stimulating the EAAT3 protein with lidocaine will produce a
reduction in symptoms in OCD patients. The current OCD model emphasizes an aberrant
glutamatergic system; stimulation of the EAAT3 protein through lidocaine could potentially
decrease the excess glutamate in the synaptic space and, as a result, diminish OCD symptoms.
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We will test our hypothesis by using in-silico docking calculations; in addition, we will identify
drug candidates that will have a stronger docking affinity to the EAAT3 protein.

2.2 Specific Aims
The specific aims are subdivided in three parts: (1) Create molecular models of the EAAT3
protein structure. Once several models are obtained, a refinement process will be applied and
the best models will be selected to identify potential binding sites. (2) Perform the docking of the
hit compound (lidocaine), evaluate the contribution of molecular contacts, and test several
parent compound constructs to further improve the molecular contacts of the binding pocket.
We will strive to create de novo ligands for the protein-binding pocket. (3) Finally we will perform
molecular dynamics calculations to assess the structural stability and find relevant motifs in the
binding of the protein-ligand complex.

Figure 4. Schematic of the computational paradigm.

2.2.1. Specific Aim 1: Homology modeling of the EAAT3 protein structure and binding site
identification.
Since there is no X-ray crystal structure, high resolution Cryo-EM, or high resolution NMR
data of the EAAT3 protein, we will use the amino acid sequence of the protein (provided in
supplemental material section) to construct the EAAT3 structure. The homology models were
produced using the following software: I-TASSER (Iterative Threading ASSEmbly Refinement),
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ModWeb, Phyre2 (Protein Homology/analogY Recognition Engine V 2.0), SWISS-MODEL, and
Schrödinger Maestro Academic Version. Even though each software has a different way of
producing a protein model, they all follow similar steps: based on the sequence imputed, the
software searches in a protein data base for proteins with similar sequences; thereafter, each
software follows a particular algorithm to match the sequence homology to the current available
structure. For more information about these algorithms, refer to supplemental material.
Once the protein models are completed, it is necessary to evaluate and refine the protein
model structure. This step is crucial to optimize the hydrogen bond network and give the
structure a low energy conformation. The first optimization will be performed using the
Schrödinger Maestro protein preparation wizard, a program that will ensure structural accuracy
by adding missing hydrogen atoms, resolving protonation states, revising bond orders, and
optimizing the hydrogen bond network.[79] We then evaluate the protein models based on the
following scores: QMEAN (the quality estimate ranges between 0 and 1, where higher values
indicate better models), Z-SCORE (compares the model to reference structures solved by X-ray
crystallography, where higher values indicate better models), and dDFIRE/dDFIRE2 (a distancescale finite ideal-gas reference, an energy scoring function where the more negative the values,
the better the model). These parameters allow us to assign a score to the protein model, which
we can use to select the best model. The results of the model quality estimation are given in
table 11 in the appendix section; additionally, the Ramachandran plot for each respective
homology model is given. The Ramachandran plot provides an overview of allowed and
disallowed regions of torsion angle values, serving as an important indicator of the quality of
protein three-dimensional structures. It is important to note that quality estimates for membrane
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proteins may receive very low Z-scores since their physico-chemical properties differ
considerably from those of soluble proteins.[10]
Analyzing the data from the homology model studies, tables 12 and 13, we selected the
best protein model from the different homology algorithms used. We then further processed the
best scoring models through another refinement process using the 3Drefine protein structure
refinement server. In this structure refinement, the hydrogen bond network is optimized and the
energy of the model is minimized using the MESHI molecular modeling package.[12] Although the
multimer homology models were not accepted by the server, the refinement process yielded five
protein structures per each refined homology model. Table 8 displays the best scores resulting
from the best protein models produced.
Table 8. Further refinement of the best models from each structure homology model algorithm. *Depicts
data from previous optimization data.

Protein Model

Best
refined
structure
from
3Drefine
server

QMEANZ-Score
Score
(dDfire/dDFIRE2)

Schrödinger
structure 1
Model 5

Schrödinger
structure 4P19

Structure
could not
be process

-3.34
(-1092.37/ 808.077)

0.484

*-1.332
(-3373.50 /2601.08)

*0.635
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Ramachandran Plot

ITASSER structure 5
Model 5

0.536

-2.70
(-1277.53/ 977.031)

0.478

-3.41
(-1078.35/ 813.615)

0.466

-3.54
(-1090.97/ 806.912)

* 0.530

* -2.62
(-3206.86 /2588.89)

Modbasestructure2
Model 3

Phyre structure 1
Model 4

Swiss server
structure 1

Structure
could not
be process

From the previous data we can conclude that the best multimeric unit is the Schrödinger
model 4P19, and the best monomeric unit is the refined ITASSER model 5. For purpose of
simplicity and to lower the burden of computational calculations, we will work with the
monomeric units for the docking and molecular mechanics studies. Additionally, we will now
refer to these models as “best” i.e. ITASSER structure 5 refinement model 5 will now be simply
be called ITASSER best.
Now that we have our protein models we will proceed to identify possible docking sites
on the protein structure, for this we used a server called Metapocket 2.0[69,70], which combines
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the power of 8 binding site predictors: LIGSITEcs, PASS, Q-SiteFinder, SURFNET, Fpocket,
GHECOM, ConCavity and POCASA. This allows the user to have a bigger range in protein binding
sites. The advantage of this server is that it calculates the z-score value for each protein binding
site and, based on this information, it discards poor binding sites form each predictor; thereafter,
it clusters the binding sites from the different predictors according to their spatial similarity. The
output from the clusters will again be ranked by the total z-score values. In this particular study,
we found several potential binding sites per each protein model; the data is provided in table 9.
Table 9. Results from the MetaPocket 2.0 binding prediction software.

Protein Model
ITASSER Best

Modbase Best

Total Z-score /(Rank)

Coordinates

12.73 / (1)

X: 82.886 Y: 69.162 Z: 85.346

6.99 / (2)

X: 80.526 Y: 73.635 Z: 76.563

4.07 / (3)

X: 76.070 Y: 74.062 Z: 91.088

2.68 / (4)

X: 88.075 Y: 76.004 Z: 85.065

2.40 / (5)

X: 83.025 Y: 55.252 Z: 86.628

16.37 / (1)

X: 7.927 Y: 9.358 Z:17.850

7.07/ (2)

X: 10.183 Y: 12.963 Z: 25.547

3.04/ (3)

X: 35.079 Y: 6.699 Z: 24.505
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Phyre Best

Schrödinger AA best

1.87/ (4)

X: 6.036 Y: 4.553 Z: 28.994

1.63 / (5)

X: 8.005 Y: -4.611 Z: -8.027

8.47 / (1)

X: 48.045 Y: 58.722 Z: -18.113

8.02 / (2)

X: 38.443 Y: 56.890 Z: -24.320

6.14 / (3)

X: 37.105 Y: 74.690 Z: -40.169

4.63 / (4)

X: 53.472 Y: 55.475 Z: -9.904

3.62 / (5)

X: 33.303 Y: 69.549 Z: -20.714

8.94 / (1)

X: 54.319 Y: 57.018 Z: -9.344

8.37 /(2)

X: 38.310 Y: 57.088 Z: -24.309

6.96 /(3)

X: 38.340 Y: 74.779 Z: -39.934

6.71 / (4)

X: 46.371 Y: 57.152 Z: -17.869

2.25 / (5)

X: 56.951 Y: 67.605 Z: -43.553
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Based on the data produced, we will use the top 3 binding sites from each protein
structure to perform the docking calculations of the hit compound and locate the most probable
binding site.

2.2.2. Specific Aim 2: Molecular docking of hit compound and novel determination of drugs
for EAAT3 protein model
With the identification of the binding sites we now proceed to dock lidocaine to find
where is the best fit among the different binding sites among the different protein models. We
have selected lidocaine (figure 5) as our hit compound because it is one of the molecules that
activate the EAAT3 transporter; additionally, lidocaine has a well-established synthetic path.
Lidocaine is a well-known voltage-gated sodium channel blocker and it works in the cell
membrane of post-synaptic neurons, preventing depolarization and inhibiting the generation and
propagation of nerve impulses.[81] Even though this molecule has been extensively studied, the
molecular binding mechanism has not been completely elucidated. Lidocaine is widely used as a
local anesthetic, but it can also be used to treat ventricular arrhythmias and acute coronary
syndrome associated with the toxicity of various stimulants.[5,79] The drug is able to cross the
blood brain barrier and can be administered topically (drug penetrates the skin and reaches the
nerves to produce analgesia without numbness), orally, inhaled, or injected. [5,79] In terms of
pharmacokinetics, the average half-life of lidocaine in adults is 1.5–2 hours; however, it may be
prolonged in patients receiving lidocaine infusions for periods longer than 24 hours.[79] Finally,
lidocaine is metabolized in the liver by de-ethylation to form monoethylglycinexylidide and
glycine xylidide, followed by cleavage of the amide bond to form xylidine and 4-hydroxyxylidine,
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which are excreted in urine. It is possible that lidocaine is binding to an important motif that locks
the EAAT3 protein in a certain conformation, allowing it to transport more glutamate.

Figure 5. Illustration of Lidocaine

The docking calculations were done with Vina AutoDock4. AutoDock4, is an empirical
scoring function that approximates the ligand binding free energy. This docking function is based
on electrostatic, Van der Waals and other functions, i.e. column energy, and internal ligand strain,
among other parameters.[60] The scoring function is provided in figure 6. The docking parameters
that we employed were the Lamarckian genetic algorithm with 2,500,000 evaluations. As for
ligand parameters, we allowed all of the possible torsion the ligand could have. We decided to
use the Lamarckian genetic algorithm because is a reliable and efficient method to predict the
docking conformation of protein ligand complexes.

Figure 6. Gibbs free energy is calculated by six pair-wise evaluations (V) and an estimate of the
conformational entropy lost upon binding. The energetic terms includes evaluations for
dispersion/repulsion, hydrogen bonding, electrostatics, and desolvation.[60]
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After docking lidocaine to the different binding sites in the different protein models, we
evaluated the protein ligand interactions. Data for the dockings of lidocaine with the target
proteins in the different binding pockets is given in table 10. Overall, if we take a close look at the
amino acids and the locations of the binding pocket of each protein, we can observe that the
binding pockets are not so far apart from one another. Figure 7 contains an illustration of the
protein with the best docking results accompanied by the amino acids interacting with the
molecule.
Table10. Molecular docking results from the molecular dockings of lidocaine with the top 3 elucidated
binding pockets.

Protein
model
ITASSER
best

Binding pocket 1

Binding pocket 2

Binding pocket 3

Coordinates of binding

Coordinates of binding

Coordinates of binding

pocket:

pocket:

pocket:

X:82.89;Y:69.16;Z:85.35

80.53 73.64 76.56

76.07 74.06 91.09

Binding_energy=-5.87

Binding energy=-5.88

Binding energy=-6.34

Ligand_Efficiency=-0.35

Ligand Efficiency=-0.35

Ligand Efficiency=-0.37

Inhib_constant=50.17u

Inhib constant=49.1uM

Inhib constant=22.55uM

M

AA involved in H-Bond:

AA involved in H-Bond:

AA involved in H-Bond:

ASN 241

GLN 252

ASN 241
Modbase
best

Coordinates of binding

Coordinates of binding

Coordinates of binding

pocket:

pocket:

pocket:

X:17.85; Y:7.93; Z: 9.36

X:35.08; Y:6.70; Z:24.51
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Binding_energy=-6.49

X:25.55; Y:10.18;

Ligand_Efficiency=-0.38

Z:12.96

Binding_energy=-5.82
Ligand_Efficiency=-0.34

Inhib_constant=17.56u

Binding_energy=-6.67

Inhib_constant=54.23uM

M

Ligand_Efficiency=-0.39

AA involved in H-Bond:

AA involved in H-Bond:

Inhib_constant=12.84u

ASN 195

Thr364 and THR 185

M
AA involved in H-Bond:
Thr364 and THR 185

Phyre
best

Schrödinger
best

Coordinates of binding

Coordinates of binding

Coordinates of binding

pocket:

pocket:

pocket:

X:48.05; Y:58.72; Z:-

X:38.44; Y:56.89; Z:-

X:37.11; Y:74.69; Z:-

18.11

24.32

40.17

Binding_energy=-6.21

Binding_energy=-5.57

Binding_energy=-5.44

Ligand_Efficiency=-0.37

Ligand_Efficiency=-0.33

Ligand_Efficiency=-0.32

Inhib_constant=28.2uM

Inhib_constant=82.51u

Inhib_constant=102.86u

AA involved in H-Bond:

M

M

ARG 447

AA involved in H-Bond:

AA involved in H-Bond:

LEU 68

VAL 20

Coordinates of binding

Coordinates of binding

Coordinates of binding

pocket:

pocket:

pocket:

X:54.32; Y:57.02; Z:-

X:38.31; Y:57.09; Z:-

X:38.34; Y:74.78; Z:-

9.34

24.31

39.93
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Binding_energy=-5.45

Binding_energy=-5.53

Binding_energy=-5.87

Ligand_Efficiency=-0.32

Ligand_Efficiency=-0.33

Ligand_Efficiency=-0.35

Inhib_constant=101.11

Inhib_constant=88.66u

Inhib_constant=50.06uM

uM

M

AA involved in H-Bond:

AA involved in H-Bond:

AA involved in H-Bond:

VAL 20

None

LEU 68

B

A

A

D

C

Figure 7. Best protein models binding pockets and amino acid interactions with lidocaine A) ITASSER model
best B) Modbase best C) Schrödinger AA best D) Phyre best. Each illustration contains a small description
of the binding pocket coordinates, binding scores, and H-bonding interactions.
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Based on the docking scores of lidocaine, we decided to create new lidocaine analogs to
develop a more stable protein-ligand binding complex. Additionally, we screened (docked)
molecular fragments to identify new compounds that will bind more efficiently to EAAT3. The
lidocaine analogs were tailored to evaluate the binding patterns and structural scaffolds of noncovalent interactions (Van der Waals, electrostatic, H-Bond, Halogen bond, and hydrophobic
bonding) in the binding pocket. Table 11 explains more in detail the purpose of each modification
and, additionally, it gives a potential synthetic scheme by which these molecules can be made.
The theory of halogen bonding states that when halogen (usually Cl, Br or I) is bonded to a strong
electron-withdrawing group, its valence shell electrons will be polarized toward the side of the
electron-withdrawing group, creating a partial positive charge in the Pz electron orbital, allowing
the halogen to act as Lewis acid; this phenomenon is known as polar flattening.[59,61] The major
advantage of halogen bonding is that it does not interfere with hydrogen bonding; however, this
is a very directional interaction.[62,63]
Table 11. Designed Docking analogs and their respective synthetic routes for further elucidation of binding
parameters of EAAT3.

Lidocaine
Analog

Rationale
We will substitute the diethyl amine motif of
lidocaine for vanillin. The purpose of this analog is to

LA1
increase the hydrophobicity, and increase the
hydrogen bond network through the structure.
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Structure

We will substitute the diethyl amine motif of
lidocaine for an aromatic complex. The objective is to
LA2

increase the hydrophobicity and aromaticity of the
molecule, producing a more feasible binding to an
important hydrophobic pocket.

We will substitute 2,6-dimethylnitrobenzene with
naphthalene to increase hydrophobicity at the other
LA3
end of the molecule, in comparison with the LA2
analog.

We will increase the bulkiness of the compound
LA4

without the π-π electron cloud of a conjugated
aromatic ring, like in the LA3 analog.
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We will increase the length of the molecule by
adding more saturated hydrocarbons, thus
LA5
increasing the surface area on which the protein
interacts with the molecule.

We will add a bromine in the 2,6dimethylnitrobenzene, in an attempt to use the
LA6
unique properties of the σ-hole produced by the
halogenated compounds.

Before beginning the binding of the lidocaine analogs, it was important to obtain a correct
molecular geometry because docking scores can be greatly affected by the structural orientation
of chemical bonds. With this in mind, we optimized the molecular geometry of the proposed
analogs to obtain a reliable molecular structure. For this optimization we used a density
functional theory calculation with a b3lyp/6-31g basis set.[64] The optimized molecules were then
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docked to the different protein models in the location where lidocaine had the highest docking
scores. The majority of the analogs increased the docking scores; however, the highest docking
scores correspond to the lidocaine anlalog 2 (LA2). The mayor advantage of this analog is the
aromatic rings that give a more planar structure to the molecule, and also increase the
hydrophobic surface area. LA3 is structurally similar to LA2 and their docking scores are close to
one another, and even though the ketone and the diethyl amine motif establish hydrogen bonds
to the binding pocket, they were not enough to surpass the hydrophobic interactions brought by
LA2. The analogs LA4 and LA5 also increase the hydrophobic surface area, but their docking
scores are the lowest among the analogs; this could be because the structures are more flexible
than in LA2, not allowing it to make contact and establish all the possible interactions available
between the alpha helixes. LA1 has an extended hydrogen bond network and it manages to
create several hydrogen bonds in the binding pocket; however, the binding pocket seemed to be
dominated by hydrophobic interactions. In the case of LA6 the halogen bond did not bring any
significant advantages to their particular binding site; this could be due to the fact that halogen
bonds are very directional and they require very strong electron-withdrawing groups to make
use of their interactions. From this analysis we can infer that the interactions in the binding
pocket are dominated by hydrophobic interactions, and that contributions from a planar
conjugated aromatic system are better able to accommodate the binding pocket.
We obtained information about the ADMET[10] (absorption, distribution, metabolism,
excretion, and toxicity) of lidocaine and the analogs. The AMED scores for lidocaine and the
analogs are provided in the appendix section E.3. All of the ADMET calculations were done using
the web servers AMEDstar, ACD/I and Schrödinger Maestro (AMED). Once we completed the
48

docking and molecular dynamic studies, we determined the best molecules based on their
binding energy and ADMET scores. This process allowed us to select a molecule that will have
low toxicity, high binding efficiency, and higher probability of being absorbed by the body. Within
the ADMET calculations, the Lipinski’s rules help in calculating the fate of a drug that is going to
be orally administered. The Lipinski’s rules are a set of rules which, if followed, might give a
molecule a higher probability to be absorbed and to permeate the cell membrane. These rules
are based on the physico-chemical properties of a molecule. The Lipinski’s rules are the following,
with no particular order: the molecular weight of the protein must not exceed 500 g/mol, the
LogPow (water/octanol partition coefficient) must be less than 5, and the number of hydrogen
bond donors/acceptors muss be less than 5/10 respectively.[65] Additionally, a polar surface area
less than 90 angstroms squared is usually needed. The Lipinsky’s rules should not be taken as a
gold standard, but rather a set of guidelines that might increase a molecule’s oral
bioavailability.[66] We have also taken into consideration the hERG score, a parameter based on
the blockade of the hERG potassium channel, which presents a significant risk of arrhythmia (QT
prolongation) in clinical application. The hERG score calculates the affinity of a particular
molecule to bind to this particular channel. If the hERG score is high, it represents a potential risk
to the patient.[67,68]
Our next goal was to create a new library of compounds to bind to the EAAT3 protein. For
this we used a program called Open Growth v0.430.[71] This programs constructs de novo ligands
by placing small organic fragments into the binding pocket. The first fragment is rotated at
random orientations in the binding pocket until the lowest score is achieved. After the first
fragment is placed, the second fragment is inputted, and once the search is complete for the
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second fragment, the program attempts to bind these 2 fragments. The search continues until N
number of fragments are inputted. In this particular study, we selected the top 10 constructed
ligands derived from the organic fragments that received the lowest scores from the data. The
program uses a knowledge-based potential to calculate binding affinities (SMOG2015). To start
the calculation, we defined the binding site of the protein models, which was the same binding
site we used to dock the lidocaine analogs. We set the parameters to construct a maximum of
200 ligands per protein model, and the library that we used to construct those ligands is the
default fragment library of 113 fragments provided by the Open Growth program. Once the
program constructs a ligand, it is going to optimize its geometry and position to better
accommodate the binding pocket. In this study, the force field used to optimize the molecules is
the MMFF94 force field; each ligand is going to be optimized 30 times with 10 iterations each
time it changes its position or moves its dihedral angle. Finally, the last parameters inputted into
the program were that the molecule must not surpass the 600 g/mol in molecular weight, and
when the growth process reached 200 ligands, it would stop the construction of ligand molecules.
The results from this program yielded 200 new ligands per protein binding pocket; since we are
using the four best protein models, we obtained 800 new ligands in total. The top ten ligands per
protein model are given in the figures below (Figure 8- Figure 11). The ligands are arranged by
their docking scores, the more negative the docking score, the more likely they are to successfully
bind to the designated binding pocket.
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Figure 8. Top ten de novo ligands created from small organic fragment molecules for the Modbase best
protein model and binding pocket.

Figure 9. Top ten de novo ligands created from small organic fragment molecules for the ITASSER best
protein model and binding pocket.
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Figure 10. Top ten de novo ligands created from small organic fragment molecules for the Phyre best
protein model and binding pocket.

Figure 11. Top ten de novo ligands created from small organic fragment molecules for the Schrödinger
best protein model and binding pocket.

Overall, we can observe that most of the new constructed ligands have similar
characteristics. Most of the ligands have aromatic rings; the most prominent feature among the
aromatic structures is the naphthalene ring fragment, which is particularly useful to increase the
hydrophobicity of the molecule. We saw the same trend when we created and docked the
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lidocaine analogs: having a naphthalene motif was very beneficial when compared to the other
modifications; however, then main disadvantage of introducing aromatic groups is that they tend
to increase the toxicity of the molecules. We can also observe that most molecules have
pyrimidine, pyridine, ketones, and tetrahydropyran fragments associated with their structure.
These particular motifs allow the molecule to extend its hydrogen bond network. Additionally,
we can also observe some fragments making use of halogens; this can be due to their halogenbonding capabilities, or simply because halogens are very electronegative groups that withdraw
electron density from allowing the atom or group that is bonded to become more electropositive,
thus allowing the possibility of electrostatic interactions to occur. The main drawback of this
study is that even though we might have created molecules that are going to have a superior
binding affinity to the target molecule, developing a synthetic scheme for these molecules can
be a cumbersome task. Overall we can observe that the top molecules all have common
characteristics. Even though the study was conducted in different protein models, with each
protein model having its own binding pocket, this is a good agreement in the qualities a good
ligand should have for it to be successful in obtaining a high binding affinity in the magnitude on
nanomoles.

2.2.3. Specific Aim 3: Molecular dynamic calculations of the best protein – ligand models
To make our results emulate the physiological conditions, and to further analyze the
docking interaction between the protein and the ligand, we performed molecular dynamics on
the docked ligands. We first placed the protein in a solvated state, neutralized the protein
charges with Na+ or Cl- ions, and surrounded it in a 1-palmitoyl-2-oleoyl-snglycero-3phosphocholine (POPC) phospholipid bilayer. The reason to use a lipid layer is because EAAT3 is
53

a membrane protein, so in physiological conditions, which we are trying to emulate, the proteins
would be embedded in a lipid membrane. Besides the lipid membrane, we also used the NPɣT
ensemble class at a temperature of 300K, pressure 1.01325 bar, and surface tension of 4000.0
bar●Å. The molecular dynamics calculation was done using the Desmond Molecular Dynamics
package, and we used the standard desmond force field parameters (figure 12). We ran the
molecular dynamics simulation for .12 nanoseconds with recording intervals of 1.2 picosecounds
to evaluate the stability of the ligand and to observe any relevant changes in conformation. With
this information, we were able to observe which molecule forms a more stable complex.

Figure 12. Mathematical representation of the DESMOND Force field.[20]
We only ran the molecular dynamics for the protein–ligand interaction of the best EAAT3 models
docked with lidocaine, our hit compound. We used the Root Mean Square Deviation (RMSD) to measure
the change in position of a selection of atoms for a particular frame with respect to a reference frame.
Figures 13-16 present the results from the molecular dynamics calculations of the best protein models
docked with lidocaine. We can observe in panel B) from all of the protein models that they don’t make
significant local changes along the protein chain.
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A)

B)

A)

C)

D)

A)

A)

Figure 13. ITASSER results for the molecular dynamic studies. A) Measure the displacement of protein
ligand complex in RMSD units as a function of time in nanoseconds. B) The pink highlighted sections of the
graph represent the secondary structure of the protein. Ligand interactions are marked in green. C) Gives
a normalized graphical representation of the protein ligand contacts to observe and identify the mayor
contributor in binding. D) Graphical representation of the mayor interactions in the binding pocket with
lidocaine.
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B)

A)
A)

C)

D)

A)

A)

Figure 14. Modbase results for the molecular dynamic studies. A) Measure the displacement of protein
ligand complex in RMSD units as a function of time in nanoseconds. B) The pink highlighted sections of the
graph represent the secondary structure of the protein. Ligand interactions are marked in green. C) Gives
a normalized bar graph representation of the protein ligand contacts to observe and identify the mayor
contributor in binding. D) Graphical representation of the mayor interactions in the binding pocket with
lidocaine.
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B)

A)
A)

C)

D)

A)

A)

Figure 15. Phyre results for the molecular dynamic studies. A) Measure the displacement of protein ligand
complex in RMSD units as a function of time in nanoseconds. B) The pink highlighted sections of the graph
represent the secondary structure of the protein. Ligand interactions are marked in green. C) Gives a
normalized graphical representation of the protein ligand contacts to observe and identify the mayor
contributor in binding. D) Graphical representation of the mayor interactions in the binding pocket with
lidocaine.
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B)

A)
A)

C)

D)

A)

A)

Figure 16. Schrodinger results for the molecular dynamic studies. A) Measure the displacement of protein
ligand complex in RMSD units as a function of time in nanoseconds. B) The pink highlighted sections of the
graph represent the secondary structure of the protein. Ligand interactions are marked in green. C) Gives
a normalized graphical representation of the protein ligand contacts to observe and identify the mayor
contributor in binding. D) Graphical representation of the mayor interactions in the binding pocket with
lidocaine.

From this study we can conclude that, even though we have different protein models and each
model has its own binding pocket, we find very similar characteristics in regard to overall structure, ligand
scores, ligand construction patterns, and molecular dynamic calculations. The elucidated binding pockets
among the different protein models make use of hydrophobic interactions to dock the ligand, and when
lidocaine is modified to have more hydrophobic groups, the docking scores increase in all protein models
in all binding pockets. We can also observe this pattern in the protein ligand contacts, which reveal that
most of the interactions are hydrophobic in nature. There might be hydrogen bonding as in the case of
ITASSER and Phyre models; however, the sum of the hydrophobic interactions surpasses the contribution
of the hydrogen bonds. Molecular dynamics also reveal that there is little conformational changes in the
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protein ligand binding pocket; however, to make this study more comprehensive, a longer molecular
dynamic calculation is needed. It is suggested to run a 10 to 15 ns molecular dynamics calculation.
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APPENDIX
A.1. EAAT3 Amino Acid Sequence.

The sequence used for the calculations was taken from the protein data bank, which
corresponds to the EAA3_HUMAN Excitatory amino acid transporter 3, derived from the gene
SLC1A1. The sequence is the following:
MGKPARKGCEWKRFLKNNWVLLSTVAAVVLGITTGVLVREHSNLSTLEKFYFAFPGEILM
RMLKLIILPLIISSMITGVAALDSNVSGKIGLRAVVYYFCTTLIAVILGIVLVVSIKPGV
TQKVGEIARTGSTPEVSTVDAMLDLIRNMFPENLVQACFQQYKTKREEVKPPSDPEMNMT
EESFTAVMTTAISKNKTKEYKIVGMYSDGINVLGLIVFCLVFGLVIGKMGEKGQILVDFF
NALSDATMKIVQIIMCYMPLGILFLIAGKIIEVEDWEIFRKLGLYMATVLTGLAIHSIVI
LPLIYFIVVRKNPFRFAMGMAQALLTALMISSSSATLPVTFRCAEENNQVDKRITRFVLP
VGATINMDGTALYEAVAAVFIAQLNDLDLGIGQIITISITATSASIGAAGVPQAGLVTMV
IVLSAVGLPAEDVTLIIAVDWLLDRFRTMVNVLGDAFGTGIVEKLSKKELEQMDVSSEVN
IVNPFALESTILDNEDSDTKKSYVNGGFAVDKSDTISFTQTSQF

A.2. Homology Structure Modeling of EAAT3

In the I-TASSER, the LOMET (Local Meta-Threading) server retrieves a template of
proteins with similar folds. Thereafter, the program retrieves fragments excised from the PDB
templates and reassembles them into full-length models by replica-exchange Monte Carlo
simulations. The unaligned regions are resolved by ab-initio models. Once the structure has been
assembled, low free-energy states are identified by SPICKER (clustering algorithm to identify the
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near-native models from protein structure decoys). The final step in this process is to remove the
steric clash, as well as to refine the global topology of the cluster centroids using TM align.[73,74,75]
In Modweb we produced 2 different models based on different algorithms. The first
protein model was derived from the provided amino acid sequence. Using PSI-BLAST (PositionSpecific Iterated BLAST) the sequence was scanned against all profiles in the template profile
database to find hits; it then used position-specific scoring matrices (PSSMs) to score matches
between query and database sequences to make the model construct. The second model was
built with the HHBlits algorithm, which is based on the pairwise alignment of hidden Markov
models (HMMs). First it searches for a multiple sequence alignment in databases for homologous
proteins; then the HHblits can build high-quality multiple sequence alignment starting from single
sequences.[86]
In the Schodinger Maestro, the sequence homology is based on the provided sequence
alignment and a provided PBD structure. We selected 2 PDB structures (PDB ID: 4P19 and 2NWX)
and to make our models, the algorithm used was the Prime STA method, which is best suited for
low sequence identity.
Phyre 2 uses the alignment of HMMs via HHsearch1 to significantly improve accuracy of
alignment and detection rate. Phyre2 also incorporates an ab-initio folding simulation called
Poing2 to model regions of the proteins with no detectable homology. [84]
In the swiss model server, the server automatically searches for structures based on Blast
and HHblits. Once the sequence alignment and the first structure is modeled, the server
optimizes the top-ranking templates using PROMOD-II and MODELLER.[87]
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Table 12. Model quality estimation for the EAAT3 protein.

Protein Model
Name

QMEANScore

I-Tasser Model 1

0.414

OPT. models
QMEANScore
0.414

I-Tasser Model 2

0.399

0.400

I-Tasser Model 3

0.418

0.418

I-Tasser Model 4

0.407

0.407

I-Tasser Model 5

0.483

0.483

Modbase PSI
Model 1

0.377

0.348

Modbase PSI
Model 2

0.443

0.436

Modbase PSI
Model 3

0.441

0.437

Modbase HHBlits
Model 1

0.358

0.355

Schrödinger
Model 1

0.433

0.466

Schrödinger
2NWX Model

0.527

0.531

Schrödinger
4P19 Model

Structure
could not
be
process
0.411

0.635

Phyre2 C4KY
Model

Z-Score
(dDfire/dDFIRE2)

OPT. models Z-Score
(dDfire/DFIRE2)

-4.15
(-1190.09/ 949.704)
-4.32
(-1169.96 /942.074)
-4.1
(-1169.67 /941.909)
-4.23
(-1184.37 /966.396)
-3.33
(-1224.74 /-963.67)
-4.65
(-1058.44 /823.483)
-3.66
(-1040.50 /788.957)
-3.70
(-1043.23 /821.786)
-4.88
(-1049.64 /824.254)
-3.81
(-1021.19 /770.618)
-2.51
(-3054.53 /2906.31)
Structure could not
be process

-3.88
(-1189.71/ -949.674)

-4.19
(-1021.14 /770.642)

-3.55
(-1021.04 /-770.512)

0.455
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-4.04
(-1169.67 /-941.909)
-3.84
(-1161.26 /-948.421)
-3.96
(-1184.13 /-966.399)
-3.33
(-1224.86 /-963.615)
-4.75
(-1059.05 /-823.756)
-3.74
(-1039.74 /-788.987)
-3.74
(-1043.88 /-821.787)
-4.67
(-1049.84 /-824.13)
-3.42
(-1021.09 /-770.487)
-2.47
(-3085.75 /-2438.23)
-1.332
(-3373.50 /-2601.08)

Phyre2 Model

0.415

0.466

Phyre2 Intensive
Model

0.395

0.383

Swiss Model 1

0.519

0.530

Swiss Model 2

0.500

0.513

Swiss Model 3

0.479

0.491

-4.15
(-1021.19 /770.618)
-4.37
(-1233.86 / 952.311)
-2.74
(-3207.98 /2588.56)
-2.99
(-3228.08 /2554.32)
-3.16
(-3281.35 /2594.54)

-3.42
(-1021.09 /-770.487)
-4.23
(-1234.65 / -952.43)
-2.62
(-3206.86 /-2588.89)
-2.83
(-2.83 -3226.09 /2554.31)
-3.02
(-3282.90 /-2594.56)

Table 13. Protein models and Ramachandran plots.

Protein Model
Name

Model

Ramachandran Plot

I-Tasser Model 1

I-Tasser Model 2
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I-Tasser Model 3

I-Tasser Model 4

I-Tasser Model 5

Modbase PSI Model
1

Modbase PSI Model
2
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Modbase PSI Model
3

Modbase HHBlits
Model 1

Schrödinger Model
1

Schrödinger 2NWX
Model

Schrödinger 4P19
Model
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Phyre2 C4KY Model

Phyre2 Model

Phyre2 Intensive
Model

Swiss Model 1

Swiss Model 2
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Swiss Model 3

A.3. Molecular Structures and Calculated Physico-Chemical Properties

Lipinski-type properties and ADMET of Lidocaine:






Molecular Weight: 234.34
No. of Hydrogen Bond Donors: 1
No. of Hydrogen Bond Acceptors: 3
Total Polar Surface Area: 32.34
No. of Rotatable Bonds: 5

Model
Blood-Brain Barrier
Human Intestinal Absorption
Caco-2 Permeability
P-glycoprotein Substrate
P-glycoprotein Inhibitor
Renal Organic Cation Transporter
CYP450 2C9 Substrate
CYP450 2D6 Substrate
CYP450 3A4 Substrate
CYP450 1A2 Inhibitor
CYP450 2C9 Inhibitor
CYP450 2D6 Inhibitor
CYP450 2C19 Inhibitor
CYP450 3A4 Inhibitor
CYP Inhibitory Promiscuity

Result
Absorption
BBB+
HIA+
Caco2+
Substrate
Non-inhibitor
Non-inhibitor
Non-inhibitor
Metabolism
Non-substrate
Substrate
Substrate
Non-inhibitor
Non-inhibitor
Non-inhibitor
Non-inhibitor
Non-inhibitor
High CYP Inhibitory
Promiscuity

79

Probability
0.8917
0.9737
0.8867
0.6680
0.8781
0.9824
0.8308
0.7721
0.8919
0.5735
0.9046
0.9231
0.9231
0.9026
0.9394
0.5770

Toxicity
Human Ether-a-go-go-Related Gene
Weak inhibitor
Inhibition
Non-inhibitor
AMES Toxicity
Non AMES toxic
Carcinogens
Carcinogens
Fish Toxicity
High FHMT
Tetrahymena Pyriformis Toxicity
High TPT
Honey Bee Toxicity
Low HBT
Biodegradation
Not ready biodegradable
Acute Oral Toxicity
II
Carcinogenicity (Three-class)
Non-required
Other Predicted Toxicity Values
Model
Value
Aqueous solubility (Absorption)
-1.8221
Caco-2 Permeability (Absorption)
1.7551
Rat Acute Toxicity
2.8382
Fish Toxicity
1.5030
Tetrahymena Pyriformis Toxicity
0.4246

0.9501
0.8604
0.8315
0.5208
0.5284
0.8455
0.8925
0.9948
0.7397
0.7165
Unit
LogS
LogPapp, cm/s
LD50, mol/kg
pLC50, mg/L
pIGC50, ug/L

Lipinski-type properties and ADME of LA 1:






Molecular Weight: 271.31
No. of Hydrogen Bond Donors: 2
No. of Hydrogen Bond Acceptors: 4
No. of Rotatable Bonds: 3
QPlogHERG: 12

Model

Result

Probability

Absorption
Blood-Brain Barrier
Human Intestinal Absorption
Caco-2 Permeability

BBB+
HIA+
Caco2+

0.8023
0.9716
0.7682

Non-substrate
Non-substrate
Substrate
Non-inhibitor
Non-inhibitor
Non-inhibitor

0.7268
0.5174
0.6194
0.6825
0.9084
0.9206

Metabolism
CYP450 2C9 Substrate
CYP450 2D6 Substrate
CYP450 3A4 Substrate
CYP450 1A2 Inhibitor
CYP450 2C9 Inhibitor
CYP450 2D6 Inhibitor
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CYP450 2C19 Inhibitor
CYP450 3A4 Inhibitor
CYP Inhibitory Promiscuity

Non-inhibitor
Non-inhibitor
High CYP Inhibitory
Promiscuity

Toxicity
Human Ether-a-go-go-Related Gene Inhibition
Weak inhibitor
Non-inhibitor
AMES Toxicity
Non AMES toxic
Carcinogens
Non-carcinogens
Fish Toxicity
High FHMT
Tetrahymena Pyriformis Toxicity
High TPT
Honey Bee Toxicity
Low HBT
Biodegradation
Not ready
biodegradable
Acute Oral Toxicity
III
Carcinogenicity (Three-class)
Non-required
Other Predicted Toxicity Values
Model
Value
Aqueous solubility (Absorption)
-3.2583
Caco-2 Permeability (Absorption)
1.4032
Rat Acute Toxicity
2.0836
Fish Toxicity
1.3803
Tetrahymena Pyriformis Toxicity
1.0061

0.8486
0.6184
0.5000

0.9935
0.7257
0.5000
0.8006
0.6417
0.9385
0.6572
0.9617
0.5351
0.4405
Unit
LogS
LogPapp, cm/s
LD50, mol/kg
pLC50, mg/L
pIGC50, ug/L

Lipinski-type properties and ADME of LA 2:






Molecular Weight: 261.36
No. of Hydrogen Bond Donors: 1
No. of Hydrogen Bond Acceptors: 1
No. of Rotatable Bonds: 3
QPlogHERG: 16

Model

Result

Probability

Absorption
Blood-Brain Barrier
Human Intestinal Absorption
Caco-2 Permeability

BBB+
HIA+
Caco2+
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0.9842
0.9946
0.7507

Metabolism
CYP450 2C9 Substrate
CYP450 2D6 Substrate
CYP450 3A4 Substrate
CYP450 1A2 Inhibitor
CYP450 2C9 Inhibitor
CYP450 2D6 Inhibitor
CYP450 2C19 Inhibitor
CYP450 3A4 Inhibitor
CYP Inhibitory Promiscuity

Non-substrate
Non-substrate
Substrate
Non-inhibitor
Inhibitor
Inhibitor
Inhibitor
Non-inhibitor
High CYP Inhibitory
Promiscuity

Toxicity
Human Ether-a-go-go-Related Gene Inhibition
Weak inhibitor
Non-inhibitor
AMES Toxicity
AMES toxic
Carcinogens
Non-carcinogens
Fish Toxicity
High FHMT
Tetrahymena Pyriformis Toxicity
High TPT
Honey Bee Toxicity
Low HBT
Biodegradation
Not ready
biodegradable
Acute Oral Toxicity
III
Carcinogenicity (Three-class)
Non-required
Other Predicted Toxicity Values
Model
Value
Aqueous solubility (Absorption)
-4.3896
Caco-2 Permeability (Absorption)
1.6271
Rat Acute Toxicity
2.6708
Fish Toxicity
0.8761
Tetrahymena Pyriformis Toxicity
0.7795

0.7758
0.5302
0.5635
0.9076
0.5509
0.6086
0.8733
0.6568
0.8717

0.8793
0.6208
0.7396
0.5977
0.9051
0.9971
0.6551
0.9630
0.6737
0.6200
Unit
LogS
LogPapp, cm/s
LD50, mol/kg
pLC50, mg/L
pIGC50, ug/L

Lipinski-type properties and ADME of LA 3:






Molecular Weight: 256.34
No. of Hydrogen Bond Donors: 1
No. of Hydrogen Bond Acceptors: 3
No. of Rotatable Bonds: 5
QPlogHERG: 10
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Model

Result

Absorption
BBB+
HIA+
Caco2+
Metabolism
CYP450 2C9 Substrate
Non-substrate
CYP450 2D6 Substrate
Non-substrate
CYP450 3A4 Substrate
Non-substrate
CYP450 1A2 Inhibitor
Inhibitor
CYP450 2C9 Inhibitor
Non-inhibitor
CYP450 2D6 Inhibitor
Non-inhibitor
CYP450 2C19 Inhibitor
Non-inhibitor
CYP450 3A4 Inhibitor
Non-inhibitor
CYP Inhibitory Promiscuity
High CYP
Inhibitory
Promiscuity
Toxicity
Human Ether-a-go-go-Related Gene Inhibition
Weak inhibitor
Non-inhibitor
AMES Toxicity
Non AMES toxic
Carcinogens
Non-carcinogens
Fish Toxicity
High FHMT
Tetrahymena Pyriformis Toxicity
High TPT
Honey Bee Toxicity
Low HBT
Biodegradation
Not ready
biodegradable
Acute Oral Toxicity
III
Carcinogenicity (Three-class)
Non-required
Other Predicted Toxicity Values
Model
Value
Aqueous solubility (Absorption)
-4.3985
Caco-2 Permeability (Absorption)
1.7201
Rat Acute Toxicity
2.2839
Fish Toxicity
1.5225
Tetrahymena Pyriformis Toxicity
0.9096
Blood-Brain Barrier
Human Intestinal Absorption
Caco-2 Permeability

Lipinski-type properties and ADME of LA 4:
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Probability
0.9821
1.0000
0.6313
0.7536
0.5508
0.5562
0.6757
0.6532
0.7723
0.5687
0.8327
0.8074

0.7965
0.6751
0.5859
0.6267
0.8763
0.9964
0.7797
0.9880
0.6021
0.6077
Unit
LogS
LogPapp, cm/s
LD50, mol/kg
pLC50, mg/L
pIGC50, ug/L







Molecular Weight: 254.41
No. of Hydrogen Bond Donors: 1
No. of Hydrogen Bond Acceptors: 3
No. of Rotatable Bonds: 6
QPlogHERG: 8

Model

Result

Probability

Absorption
Blood-Brain Barrier
Human Intestinal Absorption
Caco-2 Permeability

BBB+
HIA+
Caco2+

0.9783
0.9957
0.6397

Non-substrate
Non-substrate
Non-substrate
Non-inhibitor
Non-inhibitor
Non-inhibitor
Non-inhibitor
Non-inhibitor
Low CYP Inhibitory
Promiscuity

0.8599
0.573
0.5886
0.8246
0.9288
0.8135
0.8535
0.9113
0.817

Metabolism
CYP450 2C9 Substrate
CYP450 2D6 Substrate
CYP450 3A4 Substrate
CYP450 1A2 Inhibitor
CYP450 2C9 Inhibitor
CYP450 2D6 Inhibitor
CYP450 2C19 Inhibitor
CYP450 3A4 Inhibitor
CYP Inhibitory Promiscuity

Toxicity
Human Ether-a-go-go-Related Gene Inhibition
Weak inhibitor
Non-inhibitor
AMES Toxicity
Non AMES toxic
Carcinogens
Non-carcinogens
Fish Toxicity
Low FHMT
Tetrahymena Pyriformis Toxicity
High TPT
Honey Bee Toxicity
Low HBT
Biodegradation
Not ready
biodegradable
Acute Oral Toxicity
III
Carcinogenicity (Three-class)
Non-required
Other Predicted Toxicity Values
Model
Value
Aqueous solubility (Absorption)
-1.888
Caco-2 Permeability (Absorption)
1.2964
Rat Acute Toxicity
2.171
Fish Toxicity
2.1055
Tetrahymena Pyriformis Toxicity
-0.1532
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0.9019
0.8388
0.8182
0.6846
0.6612
0.725
0.7618
0.9873
0.7417
0.7178
Unit
LogS
LogPapp, cm/s
LD50, mol/kg
pLC50, mg/L
pIGC50, ug/L

Lipinski-type properties and ADME of LA 5:






Molecular Weight: 304.47
No. of Hydrogen Bond Donors: 1
No. of Hydrogen Bond Acceptors: 3
No. of Rotatable Bonds: 10
QPlogHERG: 6

Model

Result

Probability

Absorption
Blood-Brain Barrier
Human Intestinal Absorption
Caco-2 Permeability

BBB+
HIA+
Caco2+
Metabolism
CYP450 2C9 Substrate
Non-substrate
CYP450 2D6 Substrate
Substrate
CYP450 3A4 Substrate
Non-substrate
CYP450 1A2 Inhibitor
Non-inhibitor
CYP450 2C9 Inhibitor
Non-inhibitor
CYP450 2D6 Inhibitor
Non-inhibitor
CYP450 2C19 Inhibitor
Non-inhibitor
CYP450 3A4 Inhibitor
Non-inhibitor
CYP Inhibitory Promiscuity
Low CYP Inhibitory
Promiscuity
Toxicity
Human Ether-a-go-go-Related Gene Inhibition
Weak inhibitor
Inhibitor
AMES Toxicity
Non AMES toxic
Carcinogens
Non-carcinogens
Fish Toxicity
High FHMT
Tetrahymena Pyriformis Toxicity
High TPT
Honey Bee Toxicity
Low HBT
Biodegradation
Not ready
biodegradable
Acute Oral Toxicity
III
Carcinogenicity (Three-class)
Non-required
Other Predicted Toxicity Values
Model
Value
Aqueous solubility (Absorption)
-2.3317
85

0.8904
0.9917
0.7302
0.8126
0.6501
0.5056
0.8419
0.9501
0.5875
0.8566
0.8007
0.761

0.871
0.5
0.9006
0.6906
0.5798
0.985
0.8517
0.9846
0.7636
0.7498
Unit
LogS

Caco-2 Permeability(Absorption)
Rat Acute Toxicity
Fish Toxicity
Tetrahymena Pyriformis Toxicity

1.4992
2.1784
1.588
0.2639

LogPapp, cm/s
LD50, mol/kg
pLC50, mg/L
pIGC50, ug/L

Lipinski-type properties and ADME of LA 6:





Model

Blood-Brain Barrier
Human Intestinal Absorption
Caco-2 Permeability
CYP450 2C9 Substrate
CYP450 2D6 Substrate
CYP450 3A4 Substrate
CYP450 1A2 Inhibitor
CYP450 2C9 Inhibitor
CYP450 2D6 Inhibitor
CYP450 2C19 Inhibitor
CYP450 3A4 Inhibitor
CYP Inhibitory Promiscuity

Human Ether-a-go-go-Related Gene
Inhibition
AMES Toxicity
Carcinogens
Fish Toxicity
Tetrahymena Pyriformis Toxicity
Honey Bee Toxicity
Biodegradation

Molecular Weight: 313.23
No. of Hydrogen Bond Donors: 1
No. of Hydrogen Bond Acceptors: 3
No. of Rotatable Bonds: 5
QPlogHERG: 6
Result

Adsorption
BBB+
HIA+
Caco2+
Metabolism
Non-substrate
Non-substrate
Substrate
Non-inhibitor
Non-inhibitor
Non-inhibitor
Non-inhibitor
Inhibitor
High CYP Inhibitory
Promiscuity
Toxicity
Weak inhibitor
Inhibitor
Non AMES toxic
Non-carcinogens
High FHMT
High TPT
Low HBT
Not ready biodegradable
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Probability

0.9142
0.9672
0.7793
0.8139
0.7012
0.6031
0.6173
0.7425
0.8724
0.7808
0.915
0.8153

0.9551
0.73
0.8292
0.5104
0.7691
0.9901
0.9101
1

Acute Oral Toxicity
Carcinogenicity (Three-class)

III
Non-required
Other Predicted Toxicity Values
Model
Value
Aqueous solubility (Absorption)
-2.8825
Caco-2 Permeability (Absorption)
1.6828
Rat Acute Toxicity
2.6554
Fish Toxicity
1.2685
Tetrahymena Pyriformis Toxicity
1.0022
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0.5332
0.6517
Unit
LogS
LogPapp, cm/s
LD50, mol/kg
pLC50, mg/L
pIGC50, ug/L
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